MedPath

A clinical trial to study the effects of two drugs,vortioxetine and escitalopram in patients with major depressive disorder

Not Applicable
Completed
Conditions
Health Condition 1: F32- Major depressive disorder, singleepisode
Registration Number
CTRI/2020/01/022939
Lead Sponsor
Government medical college
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
50
Inclusion Criteria

1.First episode of major depressive disorder as per DSM-5.

2.Drug na�¯ve

3.Giving informed consent for inclusion in study

4.Age group of 18 ââ?¬â?? 55 years

5.Educated up to at least 10th standard

Exclusion Criteria

1.Any other co-morbid psychiatric illness

2.Patients with intellectual disability

3.Patients with co-morbid substance dependence excluding nicotine and caffeine

4.History of any chronic medical or surgical illness or any neurological disorder

5.Pregnant and lactating patients

6.Actively suicidal patients

7.Receiving Cognitive Enhancement Therapy, Cognitive Behavior Therapy or any psychological treatment in last 6 weeks

8.Receiving Electro Convulsive Therapy (ECT) in last 6 weeks

9.Any known hypersensitivity reaction to vortioxetine and escitalopram

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the perceived and objective cognitive deficits in patients with first episode of major depressive disorder receiving vortioxetine and escitalopram at baseline and at 6 weeks respectivelyTimepoint: At baseline and at the end of 6 weeks respectively
Secondary Outcome Measures
NameTimeMethod
To compare the perceived and objective cognitive functions in treatment <br/ ><br>responders and treatment non respondersTimepoint: At the end of 6 weeks
© Copyright 2025. All Rights Reserved by MedPath